GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012

被引：13

作者：

Gonzalez Martin, A. ^{[1
]}

Redondo, A. ^{[2
]}

Jurado, M. ^{[3
]}

De Juan, A. ^{[4
]}

Romero, I. ^{[5
]}

Bover, I. ^{[6
]}

Del Campo, J. M. ^{[7
]}

Cervantes, A. ^{[8
]}

Garcia, Y. ^{[9
]}

Lopez-Guerrero, J. A. ^{[10
]}

Mendiola, C. ^{[11
]}

Palacios, J. ^{[12
]}

Rubio, M. J. ^{[13
]}

Poveda Velasco, A. ^{[5
]}

机构：

[1] MD Anderson Canc Ctr, Dept Med Oncol, Madrid 28033, Spain

[2] Univ Hosp La Paz, Dept Med Oncol, Madrid, Spain

[3] Univ Navarra, Dept Gynecol, Sch Med, E-31080 Pamplona, Spain

[4] Univ Hosp Marques de Valdecilla, Dept Med Oncol, Santander, Spain

[5] Fundac Inst Valenciano Oncol, Dept Med Oncol, Valencia, Spain

[6] Hosp Son Llatzer, Dept Med Oncol, Palma De Mallorca, Islas Baleares, Spain

[7] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain

[8] Univ Valencia, Dept Hematol & Med Oncol, Inst Hlth Res INCLIVA, Hosp Clin Univ, Valencia, Spain

[9] Parc Tauli Healthcare Corp, Sabadell Hosp, Dept Med Oncol, Barcelona, Spain

[10] Fundac Inst Valenciano Oncol, Mol Biol Lab, Valencia, Spain

[11] Univ Hosp 12 Octubre, Dept Med Oncol, Madrid, Spain

[12] Univ Hosp Ramon & Cajal, Dept Pathol, Madrid, Spain

[13] Univ Hosp Reina Sofia, Dept Med Oncol, Cordoba, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2013年 / 15卷 / 07期

关键词：

Ovarian cancer; Treatment guidelines; Chemotherapy; Surgery; First line; Recurrent disease; PHASE-III TRIAL; PEGYLATED LIPOSOMAL DOXORUBICIN; CARBOPLATIN PLUS PACLITAXEL; GYNECOLOGIC-ONCOLOGY-GROUP; ADVANCED-STAGE OVARIAN; EPITHELIAL OVARIAN; 1ST-LINE TREATMENT; ADJUVANT CHEMOTHERAPY; INTERGROUP TRIAL; INTRAPERITONEAL CISPLATIN;

D O I：

10.1007/s12094-012-0995-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In 2006, under the auspices of The Spanish Research Group for Ovarian Cancer (Spanish initials GEICO), the first "Treatment Guidelines in Ovarian Cancer" were developed and then published in Clinical and Translational Oncology by Poveda Velasco et al. (Clin Transl Oncol 9(5):308-316, 2007). Almost 6 years have elapsed and over this time, we have seen some important developments in the treatment of ovarian cancer. Significant changes were also introduced after the GCIG-sponsored 4th Consensus Conference on Ovarian Cancer by Stuart et al. (Int J Gynecol Cancer 21:750-755, 2011). So we decided to update the treatment guidelines in ovarian cancer and, with this objective, a group of investigators of the GEICO group met in February 2012. This study summarizes the presentations, discussions and evidence that were reviewed during the meeting and during further discussions of the manuscript.

引用

页码：509 / 525

页数：17

共 99 条

[1] Chemotherapy for ovarian cancer - a consensus statement on standard practice [J].

Adams, M ;

Calvert, AH ;

Carmichael, J ;

Clark, PI ;

Coleman, RE ;

Earl, HM ;

Gallagher, CJ ;

Ganesan, TS ;

Gore, ME ;

Graham, JD ;

Harper, PG ;

Jayson, GC ;

Kaye, SB ;

Ledermann, JA ;

Osborne, RJ ;

Perren, TJ ;

Poole, CJ ;

Radford, JA ;

Rustin, GJS ;

Slevin, ML ;

Smyth, JF ;

Thomas, H ;

Wilkinson, PM .

BRITISH JOURNAL OF CANCER, 1998, 78 (11) :1404-1406

[2] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].

Aghajanian, Carol ;

Blank, Stephanie V. ;

Goff, Barbara A. ;

Judson, Patricia L. ;

Teneriello, Michael G. ;

Husain, Amreen ;

Sovak, Mika A. ;

Yi, Jing ;

Nycum, Lawrence R. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2039-2045

[3] Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].

Alberts, DS ;

Liu, PY ;

Hannigan, EV ;

OToole, R ;

Williams, SD ;

Young, JA ;

Franklin, EW ;

ClarkePearson, DL ;

Malviya, VK ;

DuBeshter, B ;

Adelson, MD ;

Hoskins, WJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955

[4]

American College of Obstetricians and Gynecologists, 2007, Obstet Gynecol, V110, P201

[5]

[Anonymous], CANC RES, V60, P7052

[6] Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].

Armstrong, DK ;

Bundy, B ;

Wenzel, L ;

Huang, HQ ;

Baergen, R ;

Lele, S ;

Copeland, LJ ;

Walker, JL ;

Burger, RA .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43

[7] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].

Atkinson, AJ ;

Colburn, WA ;

DeGruttola, VG ;

DeMets, DL ;

Downing, GJ ;

Hoth, DF ;

Oates, JA ;

Peck, CC ;

Schooley, RT ;

Spilker, BA ;

Woodcock, J ;

Zeger, SL .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95

[8] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[9] Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study [J].

Bell, Jeffrey ;

Brady, Mark F. ;

Young, Robert C. ;

Lage, Janice ;

Walker, Joan L. ;

Look, Katherine Y. ;

Rose, G. Scott ;

Spirtos, Nick M. .

GYNECOLOGIC ONCOLOGY, 2006, 102 (03) :432-439

[10]

Berek J S, 2000, Gynecol Obstet Fertil, V28, P576

← 1 2 3 4 5 6 7 8 9 10 →